DiaMedica Therapeutics (DMAC)
(Delayed Data from NSDQ)
$4.13 USD
+0.09 (2.23%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $4.13 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.13 USD
+0.09 (2.23%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $4.13 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth B Momentum D VGM
Zacks News
Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Atossa Genetics Inc. (ATOS) and DiaMedica Therapeutics, Inc. (DMAC) have performed compared to their sector so far this year.
Are Medical Stocks Lagging DiaMedica Therapeutics (DMAC) This Year?
by Zacks Equity Research
Here is how DiaMedica Therapeutics, Inc. (DMAC) and Elutia Inc. (ELUT) have performed compared to their sector so far this year.
DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch
by Zacks Equity Research
DiaMedica (DMAC) rises 10% as it doses the first patient in the relaunch of its pivotal study evaluating the lead candidate, DM199, to treat acute ischemic stroke.
DiaMedica Therapeutics (DMAC) Loses -19.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
DiaMedica Therapeutics (DMAC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Cardiol Therapeutics Inc. (CRDL) and DiaMedica Therapeutics, Inc. (DMAC) have performed compared to their sector so far this year.
Is DiaMedica Therapeutics (DMAC) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how DiaMedica Therapeutics, Inc. (DMAC) and DermTech, Inc. (DMTK) have performed compared to their sector so far this year.
What Makes DiaMedica Therapeutics, Inc. (DMAC) a New Buy Stock
by Zacks Equity Research
DiaMedica Therapeutics, Inc. (DMAC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
DiaMedica (DMAC) Initiates Pivotal Ischemic Stroke Study
by Zacks Equity Research
DiaMedica (DMAC) is developing its recombinant KLK1 protein candidate, DM199 for treating patients who suffered an acute ischemic stroke in the last 24 hours as well as for reducing the risk of recurrent stroke.
New Strong Sell Stocks for July 21st
by Zacks Equity Research
CNO, CLOV, DMAC, HCAT and IMAX have been added to the Zacks Rank #5 (Strong Sell) List on July 21, 2021.
Moving Average Crossover Alert: DiaMedica Therapeutics (DMAC)
by Zacks Equity Research
DiaMedica Therapeutics (DMAC) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Is the Options Market Predicting a Spike in DiaMedica (DMAC) Stock?
by Zacks Equity Research
Investors need to pay close attention to DiaMedica (DMAC) stock based on the movements in the options market lately.
New Strong Sell Stocks for April 20th
by Zacks Equity Research
ATTO, DMAC, DG, GEL, and IAG have been added to the Zacks Rank #5 (Strong Sell) List on April 20, 2021